Epilepsy. Epilepsy and recurrent seizures
Conditions
Interventions
Intervention 1: Intervention group: in this study consists of patients with seizure disorders who receive the End Self-Stigma (ESS) group intervention. ESS is a structured, non-pharmacological group
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Definitive diagnosis of seizures by a neurologist Ages 18 to 60 years individuals who experience distress due to the stigma associated with this disorder will be included in the intervention. Minimum education: high school diploma Ability to attend group sessions regularly Provision of written informed consent.
Exclusion criteria
Exclusion criteria: Concurrent diagnosis of epilepsy with other neurocognitive disorders (confirmed by a neurologist) Presence of active psychotic or bipolar disorders (assessed by SCID-5) Risk of suicide (score above 15 on the Beck Suicide Scale) Substance abuse or dependence in the past 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome of this study is to examine the effect of the ESS group intervention on reducing internalized stigma in patients with epilepsy by comparing ISMI questionnaire scores before and immediately after the intervention. Timepoint: Before studying, During studying, 3 months after studying. Method of measurement: Measurement with the fingertip scale) (Assessment with the Connor-Davidson Resilience Scale questionnaire) (Evaluation with the WHO-QOL questionnaire)4. (Assessment with the BAI questionnaire)5. (Evaluation with the BDI-II questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Resilience As a secondary outcome, the effect of the ESS group intervention on the level of resilience in patients with seizure disorders will be evaluated by comparing scores on the Connor–Davidson Resilience Scale (CD-RISC) before the intervention, immediately after the intervention, and at the three-month follow-up. Timepoint: Before studying, During studying, 3 months after studying. Method of measurement: Level of resilience (assessed with the Connor-Davidson Resilience Scale).;Quality of Life : As a secondary outcome, changes in patients’ quality of life following the ESS group intervention will be assessed using the WHOQOL-BREF questionnaire at three time points: pre-intervention, post-intervention, and three-month follow-up. Timepoint: Before studying, During studying, 3 months after studying. Method of measurement: Quality of life (evaluated with the WHO-QOL questionnaire).;Anxiety : Another secondary outcome of this study is to examine the effect of the ESS group intervention on the severity of anxiety symptoms in patients with seizure disorders, as measured by comparing scores on the Beck Anxiety Inventory (BAI) across three assessment time points. Timepoint: Before studying, During studying, 3 months after studying. Method of measurement: Level of anxiety (measured with the BAI question).;Depression : Changes in the severity of depressive symptoms will be evaluated as a secondary outcome by comparing scores on the Beck Depression Inventory-II (BDI-II) before the intervention, immediately after the intervention, and at the three-month follow-up. Timepoint: Before studying, During studying, 3 months after studying. Method of measurement: . Severity of depression (assessed with the BDI-II questionnaire).;Sustainability of Intervention EffectsThe sustainability of the effects of the ESS group intervention will be examined as a secondary outcome by comparing post-intervention scores with those obtained at the three-month follow-up. Timepoint: Before the inter | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHoma Khazaei
Mashhad University of Medical Sciences
Outcome results
None listed